ANDA ANDA, founded in 1992, has become the 4th largest distributor of generic pharmaceuticals in the U.S. With over 7,000 items in stock, our product assortment also includes select brands, vaccines, injectables,...
Atlantic Biologicals Atlantic Biologicals is a comprehensive provider of healthcare solutions. The company is a premier distributor of brand, generic and critical care pharmaceuticals as well as medical-surgical supplies and diagnostic...
Kinray Kinray, Inc. is the largest privately-held distributor of pharmaceutical, generic, health & beauty and home health care products in the world. The Kinray team has a long standing and proud tradition of providing reliable,...
Capitol Scientific, Inc. Capitol Scientific is a goal-oriented team of dedicated, positive, and successful individuals focused on helping our customers achieve their goals. By encouraging innovation and initiative in our employees, we are always...
Confab Laboratories Confab is recognized as much for the excellence of its products and services as for its capacity to deliver large volumes of manufactured and packaged products on time.
Using the latest technologies, Confab excels...
AmerisourceBergen Corporation AmerisourceBergen Corporation is based in Valley Forge, PA and has locations throughout the United States, Puerto Rico, Canada, and the United Kingdom. In the US, we handle about 20% of all of the pharmaceuticals sold...
Calibrate, Inc. Calibrate, Inc. founded the pipette calibration and service industry in 1984 and remains North America's leader in the business. No one knows pipettes better. Our prices are competitive and the quality of service is...
Prescription drug development continues to increase in importance. In 2006, U.S. biopharmaceutical companies invested $56.1 billion in research and development of which $44.9 billion was conducted in the U.S.1 In 2008 alone, the U.S. Food & Drug Administration approved 24 new drugs.2 Pharmaceutical, biotechnology, chemical and healthcare companies are involved in the effort to identify new ...
THE SCORR: Although this campaign has received national advertising awards for its cre- ative merit and execution, the true measure of success is in a return on invest- ment for Camargo. In that regard, it has exceeded all expectations.
The “old dog, new tricks” approach served to solidify Camargo’s standing in the industry as experts in 505(b)(2) and continues to be the platform from which the ...
FDA Accredited Persons Third-Party Inspection Program (TPI) To ensure that appropriate medical device manufacturing conditions and controls are in place, the U.S. Food, Drug and Cosmetic Act established a requirement that the FDA inspect manufacturers of Class II and III Medical Devices at least once every two years. Due to limited resources and significant growth of the Medical Device Industry, ...
Pharmaceutical manufacturing executives today are all too familiar with industry regulations such as Title 21 CFR Part 11 and current good manufacturing practices (cGMPs). However, many drug companies still struggle to comply with these and other U.S. Food and Drug Administration (FDA) requirements.
In 2008 alone, the FDA issued 43 warning letters to pharmaceutical companies for regulatory ...
Aptuit Informatics 29219 Canwood Street, Suite 120 Agoura Hills, CA 91301 USA Tel: +1 818.879.0075 Fax: +1 818.879.7303
Information contained herein is proprietary to Aptuit Informatics, Inc. Ideas, concepts, designs, methods and the like are the intellectual property of Aptuit Informatics, Inc. and as such are protected by US and international copyright laws as well as US and international laws ...
FDA issued a guidance document entitled “Adverse Reactions Section Labeling for Human Prescription Drug and Biological Products – Content and Format” in January 2006. The guidance is intended to assist both applicants and reviewers draft the Adverse Reactions section of the prescribing information in the new format specified by the labeling rule finalized in January 2006 and effective June 2006. ...
CFR Title 21 Food & Drugs • Part 312: Investigational INDs (IND) • Part 314: New Drug Applications (NDA)
• Directive 2001/83/EC (Medicinal Products) • Directive 2001/20/EC (Clinical Trials) • Each country must adopt laws and regulations to comply with the EU Directives
Application Required for Investigational Trial
Single Initial IND Application per Phase 1 Indication • IND remains open • New ...
Noroxycodone Abstract An HPLC-MS/MS method was developed and validated for oxycodone and two of its active metabolites, oxymorphone and noroxycodone, in plasma at ABC-Europe in the range of 0.200 - 100 ng/mL.The method was subsequently validated at ABC-US.
In the wake of the recent spate of drug withdrawals and other drug safety issues, there have been renewed calls to reform and enhance the U.S. approach to monitoring safety issues in marketed products. These calls have come from many quarters, and a variety of initiatives have been the result.
Soon after the financial meltdown began late last fall, J. Leslie Glick, Ph.D. (see sidebar on profile of Dr. Glick), who is a staunch supporter of capitalization and free enterprise, proposed the government provide stimulus monies to VC firms to ensure the continued growth and financial stability of the U.S. life sciences industry. In exchange for taxpayer investment in these firms, the federal ...
For precision, reliability and simplicity in liquid handling technology, CyBio provides automated systems for drug discovery and life sciences research. ...
Company descriptions and contact
information are quoted
from the company's website or other promotional information. JAZ'D is not responsible for
the accuracy
of this information. Unless specifically noted, JAZ'D is not sponsored by, affiliated with
or otherwise
connected with any of the listed companies.
